Short Bowel Syndrome Market Research Key Players Patrick Roy Canada Jersey , Industry Overview and forecasts to 2024 by Metcarl · October 10, 2018
Global Short Bowel Syndrome Market: Snapshot
Short bowel syndrome (SBS) refers to a disorder that occurs due to the malfunction of the intestine, leading to malabsorption. SBS can be an outcome of various underlying diseases or medical conditions that can cause resection of the intestine. Owing to this the nutrient processing areas in the intestine rendered dysfunction and can lead to dangerous infectious and metabolic disorders. The research report predicts that the global short bowel syndrome market is expected to rise at a CAGR of 30.4% to reach a valuation of US$2.6 bn by the end of 2024 as compared to be US$312.7 mn in 2016.
View Report-
The disease can be congenital or can be a result of underlying diseases such as Crohn鈥檚 disease, intestinal failure, tumors, injury or trauma to the small intestine. Necrotizing enterocholitis is observed to be the cause of short bowel syndrome amongst neonates and infants. The research report estimates that the postoperative complications arising out of vascular and obstructive anomalies, which need extensive resection have been on the rise. These complications have also been making a significant contribution to high prevalence SBS across the globe.
GLP-2 Emerges as Popular Drug Class due to Approvals in North America and Europe
On the basis of drugs Patrick Marleau Canada Jersey , the global short bowel syndrome market is segmented into GLP-2, growth hormone, glutamine, and others. Presently, GLP-2 is leading the global market due to its wide presence in the U.S. and Europe. The GLP-2 drug, composed of teduglutide as the primary ingredient, is sold under the brand name of Gattex in the U.S. and as Revestive in Europe and other international markets. The other drugs available for SBS in the U.S. market are Zorbtive (growth hormone) and NutreStore (Glutamine). However Patrice Bergeron Canada Jersey , Revestive is the sole drug designed for specifically treating SBS. Owing to the specificity of these drugs and their wide availability in the regions, these drugs are expected to make significant contributions to the rising revenue of the global market during the forecast period. The drugs currently have an orphan drug status and thus enjoy drug exclusivity that has a growing pool of patients. Presently, this drug has also reached phase III of clinical trials in Japan, which could open up several lucrative opportunities to treat adults as well as infants.
Request A Sample-
;rep_id=13346
North America Retains Lead due to Increasing Prescriptions for Gattex Therapy
In terms of geography, the global short bowel syndrome market is fragmented into North America, Europe, and Rest of the World. Of these P.K Subban Canada Jersey , North America is expected to dominate the global market in the coming years. The increasing prescriptions for Gattex therapy in the U.S. is expected to be the key growth driver for the North America short bowel syndrome market. Furthermore, the fact that glutamine and growth hormone are only approved in the U.S. for treating SBS is expected to keep North America in the lead. The growing awareness about short bowel syndrome amongst consumers and excellent reimbursement strategies are expected to drive the regional market in the coming years.
The key players operating in the global short bowel syndrome market are Shire plc, Merck KGaA, and Emmaus Life Sciences, Inc. As of 2015, Shire held a whopping share of 50% in the overall market with its blockbuster drugs, making the competitive landscape fairly competitive. The other important players operating in the global market are Nutrinia Ltd Mike Smith Canada Jersey , GlyPharma Therapeutics, OxThera, Ardelyx, Inc., Sancilio & Company, Inc., Naia Pharmaceuticals Maurice Richard Canada Jersey , and Zealand Pharma AS.
Request Brochure-
;rep_id=13346 KVM over IP Market Research Report : Global Analysis 2019-2024
by Salamatt Singh · June 24, 2019
The latest trending report Global KVM over IP Market 2019-2024 added by
A KVM switch (with KVM being an abbreviation for keyboard, video and mouse) is a hardware device that allows a user to control multiple computers from one or more keyboard, video monitor and mouse. Although multiple computers are connected to the KVM, typically a smaller number of computers can be controlled at any given time.
The worldwide market for KVM over IP is expected to grow at a CAGR of roughly 8.1% over the next five years, will reach 570 million US$ in 2024, from 350 million US$ in 2019.
This report focuses on the KVM over IP in global market Matt Duchene Canada Jersey , especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Browse the complete report and table of contents @聽
Market Segment by Manufacturers, this report covers
North America (United States, Canada and Mexico) Europe (Germany, France, UK, Russia and Italy) Asia-Pacific (China, Japan, Korea Mark Messier Canada Jersey , India and Southeast Asia) South America (Brazil, Argentina, Colombia etc.) Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Star Trek Bridge Commander Modding
Thema drucken
14.12.2019 04:19
Antworten
